These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8032959)

  • 1. Phase II study of orchiectomy combined with epirubicin as first-line treatment in advanced prostate carcinoma.
    Leliefeld H; Wils J; Peulen G; Smeets J
    Cancer Invest; 1994; 12(4):395-8. PubMed ID: 8032959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of epirubicin in advanced hormone-resistant prostatic carcinoma.
    Delaere KP; Leliefeld H; Peulen F; Stapper EW; Smeets J; Wils J
    Br J Urol; 1992 Dec; 70(6):641-2. PubMed ID: 1486391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II multicenter study of epirubicin for hormone-resistant prostatic cancer with measurable soft tissue disease.
    Tannock IF; Erwin TJ; Stewart DJ; Fontaine B; Gupta S
    Am J Clin Oncol; 1993 Apr; 16(2):156-8. PubMed ID: 8452110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
    N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.
    Pummer K
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):26-8. PubMed ID: 1948120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.
    Janknegt RA; Boon TA; van de Beek C; Grob P
    Urology; 1997 Mar; 49(3):411-20. PubMed ID: 9123707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group.
    Brausi M; Jones WG; Fosså SD; de Mulder PH; Droz JP; Lentz MA; van Glabbeke M; Pawinski A
    Eur J Cancer; 1995 Sep; 31A(10):1622-6. PubMed ID: 7488412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer.
    Hausmaninger H; Lehnert M; Steger G; Sevelda P; Tschurtschenthaler G; Hehenwarter W; Fridrik M; Samonigg H; Schiller L; Manfreda D
    Eur J Cancer; 1995 Dec; 31A(13-14):2169-73. PubMed ID: 8652237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group.
    Di Leo A; Bajetta E; Buzzoni R; Bochicchio AM; Nolè F; Biganzoli L; D'Aprile M; Veltri E; Comella G; Aitini E
    Am J Clin Oncol; 1995 Jun; 18(3):239-44. PubMed ID: 7538260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of epirubicin in advanced soft tissue sarcoma.
    Chevallier B; Montcuquet P; Fachini T; Nguyen Bui B; Kerbrat P; Bastit P; Vo Van ML
    Bull Cancer; 1990; 77(10):991-5. PubMed ID: 2249019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study.
    Carmo-Pereira J; Costa FO; Miles DW; Henriques E; Richards MA; Rubens RD
    Cancer Chemother Pharmacol; 1991; 27(5):394-6. PubMed ID: 1999000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly chemotherapy in advanced prostatic cancer.
    Francini G; Petrioli R; Manganelli A; Cintorino M; Marsili S; Aquino A; Mondillo S
    Br J Cancer; 1993 Jun; 67(6):1430-6. PubMed ID: 8512828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
    Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
    Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.
    Takashima S; Saeki T; Adachi I; Watanabe T; Sasaki Y; Murai H; Tabei T; Ogita M; Sano M; Kanda K; Shimoyama M
    Jpn J Clin Oncol; 1997 Oct; 27(5):325-30. PubMed ID: 9390210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial.
    Ostri P; Bonnesen T; Nilsson T; Frimodt-Møller C
    Urol Int; 1991; 46(2):167-71. PubMed ID: 1711250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
    Gasparini G; Dal Fior S; Panizzoni GA; Favretto S; Pozza F
    Am J Clin Oncol; 1991 Feb; 14(1):38-44. PubMed ID: 1987737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.